X4 PHARMACEUTICALS, INC (XFOR) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $96.00K; Additional Paid in Capital, Common StockUSD $786.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-123.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $94.00K; Additional Paid in Capital, Common StockUSD $783.27M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-122.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $91.00K; Additional Paid in Capital, Common StockUSD $780.86M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-109.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $25.00K; Additional Paid in Capital, Common StockUSD $632.34M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-118.00K.
X4 PHARMACEUTICALS, INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Fair Value USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $96.00K | $786.43M | $-123.00K | $-630.95M | $155.45M | 3 month · $3.09M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $94.00K | $783.27M | $-122.00K | $-614.79M | $168.45M | 3 month · $2.41M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $91.00K | $780.86M | $-109.00K | $-594.55M | $186.29M | 12 month · $4.30M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $25.00K | $632.34M | $-118.00K | $-570.63M | $61.62M | 3 month · $760.00K | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $8.00K | $544.91M | $-138.00K | $-540.81M | $3.97M | 3 month · $748.00K | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $6.00K | $538.14M | $-128.00K | $-515.07M | $22.94M | 3 month · $519.00K | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $6.00K | $537.62M | $-122.00K | $-515.36M | $22.15M | 12 month · $8.20M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $168.00K | $535.10M | $-114.00K | $-475.53M | $59.62M | 3 month · $1.82M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $168.00K | $533.28M | $-159.00K | $-438.84M | $94.45M | 3 month · $2.43M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $168.00K | $530.69M | $-155.00K | $-529.67M | $1.04M | 3 month · $1.74M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $167.00K | $528.96M | $-119.00K | $-477.90M | $51.10M | 12 month · $8.69M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $165.00K | $526.32M | $-119.00K | $-458.77M | $67.59M | 3 month · $2.36M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $164.00K | $523.96M | $-119.00K | $-456.47M | $67.53M | 3 month · $2.14M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $122.00K | $452.43M | $-119.00K | $-400.76M | $51.68M | 3 month · $1.65M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $122.00K | $450.79M | $-119.00K | $-376.74M | $74.05M | 12 month · $5.20M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $69.00K | $409.53M | $-119.00K | $-347.63M | $61.85M | 3 month · $1.11M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $31.00K | $356.21M | $-119.00K | $-326.05M | $30.07M | 3 month · $1.52M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $31.00K | $354.64M | $-119.00K | $-304.84M | $49.71M | 3 month · $1.46M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $28.00K | $347.37M | $-119.00K | $-282.87M | $64.41M | 12 month · $6.18M | $0.00 | (m) | (m) |
| 2021-09-30 | (m) | $25.00K | $321.44M | $-119.00K | $-252.66M | $68.68M | 3 month · $1.52M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $25.00K | $319.92M | $-119.00K | $-232.49M | $87.34M | 3 month · $1.80M | (m) | 3 month · $3.50M | (m) |
| 2021-03-31 | (m) | $24.00K | $318.01M | $-119.00K | $-212.85M | $105.06M | 3 month · $1.26M | (m) | 3 month · $3.50M | (m) |
| 2020-12-31 | (m) | $16.00K | $267.08M | $-119.00K | $-194.18M | $72.80M | 12 month · $5.43M | $0.00 | (m) | (m) |
| 2020-09-30 | (m) | $16.00K | $265.59M | $-119.00K | $-175.78M | $89.71M | 3 month · $2.24M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $16.00K | $263.31M | $-119.00K | $-158.33M | $104.88M | 3 month · $1.17M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $16.00K | $262.08M | $-119.00K | $-143.18M | $118.79M | 3 month · $613.00K | (m) | (m) | (m) |
| 2019-12-31 | (m) | $16.00K | $261.37M | $-119.00K | $-132.04M | $129.22M | 12 month · $2.05M | $0.00 | (m) | 12 month · $817.00K |
| 2019-09-30 | (m) | $12.00K | $200.42M | $-119.00K | $-121.21M | $79.11M | 3 month · $691.00K | $0.00 | (m) | (m) |
| 2019-06-30 | (m) | $13.00K | $199.69M | $-42.00K | $-103.49M | $96.17M | 3 month · $433.00K | $0.00 | (m) | (m) |
| 2019-03-31 | (m) | $7.00K | $119.52M | $23.00K | $-90.11M | $29.44M | 3 month · $262.00K | $0.00 | (m) | 3 month · $817.00K |
| 2018-12-31 | (m) | $0.00 | $2.15M | $0.00 | $-79.24M | $-77.09M | 12 month · $759.00K | (m) | (m) | (m) |
| 2018-09-30 | (m) | $14.00K | $153.67M | $144.00K | $-125.93M | $-66.09M | 3 month · $198.00K | (m) | (m) | (m) |
| 2018-06-30 | (m) | $14.00K | $152.60M | $177.00K | $-115.03M | $-57.69M | 3 month · $145.00K | (m) | (m) | (m) |
| 2018-03-31 | (m) | $15.00K | $151.40M | $-93.00K | $-102.89M | $-51.81M | 3 month · $128.00K | (m) | (m) | (m) |
| 2017-12-31 | (m) | $15.00K | $150.83M | $127.00K | $-92.27M | $-44.55M | 12 month · $492.00K | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-23.05M | 12 month · $644.00K | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $-34.32M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |